JP2015521157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521157A5 JP2015521157A5 JP2015504599A JP2015504599A JP2015521157A5 JP 2015521157 A5 JP2015521157 A5 JP 2015521157A5 JP 2015504599 A JP2015504599 A JP 2015504599A JP 2015504599 A JP2015504599 A JP 2015504599A JP 2015521157 A5 JP2015521157 A5 JP 2015521157A5
- Authority
- JP
- Japan
- Prior art keywords
- cftr
- subject
- mucociliary clearance
- kit
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims 11
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 11
- 230000000420 mucociliary effect Effects 0.000 claims 8
- 230000005856 abnormality Effects 0.000 claims 5
- 239000012190 activator Substances 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 5
- 230000009395 genetic defect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 210000001552 airway epithelial cell Anatomy 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 238000012261 overproduction Methods 0.000 claims 1
- 230000010349 pulsation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621043P | 2012-04-06 | 2012-04-06 | |
| US61/621,043 | 2012-04-06 | ||
| PCT/US2013/032268 WO2013151758A2 (en) | 2012-04-06 | 2013-03-15 | Methods for increasing cftr activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521157A JP2015521157A (ja) | 2015-07-27 |
| JP2015521157A5 true JP2015521157A5 (enExample) | 2016-05-12 |
| JP6525203B2 JP6525203B2 (ja) | 2019-06-05 |
Family
ID=49301152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504599A Expired - Fee Related JP6525203B2 (ja) | 2012-04-06 | 2013-03-15 | Ｃｆｔｒ活性を増大させるための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150065539A1 (enExample) |
| EP (1) | EP2833885A4 (enExample) |
| JP (1) | JP6525203B2 (enExample) |
| CN (1) | CN104619321A (enExample) |
| AU (2) | AU2013243857A1 (enExample) |
| CA (1) | CA2869257A1 (enExample) |
| HK (1) | HK1206995A1 (enExample) |
| WO (1) | WO2013151758A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| CA2963945C (en) | 2014-10-07 | 2023-01-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH690023A5 (de) * | 1996-02-02 | 2000-03-31 | Medichemie Ag | Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut. |
| US20040266883A1 (en) * | 1999-10-27 | 2004-12-30 | Yale University | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US7541466B2 (en) * | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| RS56894B1 (sr) | 2008-08-13 | 2018-04-30 | Vertex Pharma | Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| RU2012114323A (ru) * | 2009-09-12 | 2013-10-20 | РЕКИТТ БЕНКИЗЕР ЭлЭлСи | Применение гвайфенезина для ингибирования секреции муцина |
| KR101924162B1 (ko) * | 2010-03-15 | 2018-11-30 | 버지니아 커먼웰스 유니버시티 | 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손 |
| CN103180298A (zh) * | 2010-03-19 | 2013-06-26 | 沃泰克斯药物股份有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式 |
| ME03652B (me) * | 2011-05-18 | 2020-07-20 | Vertex Pharmaceuticals Europe Ltd | Deuterisani derivati ivakaftora |
-
2013
- 2013-03-15 WO PCT/US2013/032268 patent/WO2013151758A2/en not_active Ceased
- 2013-03-15 CA CA2869257A patent/CA2869257A1/en not_active Abandoned
- 2013-03-15 AU AU2013243857A patent/AU2013243857A1/en not_active Abandoned
- 2013-03-15 HK HK15107706.3A patent/HK1206995A1/xx unknown
- 2013-03-15 JP JP2015504599A patent/JP6525203B2/ja not_active Expired - Fee Related
- 2013-03-15 US US14/387,818 patent/US20150065539A1/en not_active Abandoned
- 2013-03-15 CN CN201380023856.4A patent/CN104619321A/zh active Pending
- 2013-03-15 EP EP13772725.1A patent/EP2833885A4/en not_active Withdrawn
-
2017
- 2017-04-28 US US15/582,260 patent/US10300052B2/en not_active Expired - Fee Related
-
2018
- 2018-01-10 AU AU2018200192A patent/AU2018200192B9/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giger et al. | Biomedical applications of bisphosphonates | |
| Schanté et al. | Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications | |
| SG10201803833WA (en) | Heterocyclic compounds useful in the treatment of disease | |
| JP2016528301A5 (enExample) | ||
| JP2014517008A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2014221779A5 (enExample) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2016517888A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2018519245A5 (enExample) | ||
| JP2017518302A5 (enExample) | ||
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| JP2013500986A5 (enExample) | ||
| JP2013079282A5 (enExample) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2015514781A5 (enExample) | ||
| JP2014515351A5 (enExample) | ||
| EA201400521A1 (ru) | Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| JP2017500289A5 (enExample) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2015516419A5 (enExample) | ||
| JP2014506582A5 (enExample) | ||
| JP2017014206A5 (enExample) |